$19.53
Price
$990M
Market Cap
34.3
P/E Ratio
11.6
Forward P/E
$0.57
EPS (TTM)
—
Dividend Yield
$330M
Cash
$50M
Total Debt
51M
Shares Out
$7.90
$21.03
52-Week Range
Institutional Ownership of THERAVANCE BIOPHARMA INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for THERAVANCE BIOPHARMA INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2022-Q3 | |||||
| SELL | EXIT | — | — | $9.34 | |
| 2022-Q2 | |||||
| SELL | -6.3% | 28.1M | $26M | $9.10 | |
Insider Trading for THERAVANCE BIOPHARMA INC
6 Months Insider Sentiment
Buy $0
Sell $2.3M
0
Buys
8
Sells
-2.3M
Net
1
Grants
Largest
$546K
Broshy
$310K
Broshy
$291K
Farnum
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 03, 2025 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | SELL | 7.8K | $18.75 | $146K |
| Dec 03, 2025 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | SELL | 15.5K | $18.75 | $291K |
| Dec 03, 2025 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | SELL | 7.8K | $18.75 | $146K |
| Nov 26, 2025 | Eran Broshy | Director | SELL | 14.0K | $20.00 | $280K |
| Nov 26, 2025 | Eran Broshy | Director | SELL | 15.5K | $20.00 | $310K |
| Nov 19, 2025 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | GRANT | 9.9K | — | — |
| Nov 11, 2025 | Eran Broshy | Director | SELL | 29.5K | $18.50 | $546K |
| Nov 11, 2025 | Eran Broshy | Director | SELL | 15.5K | $18.50 | $287K |
| Nov 11, 2025 | Eran Broshy | Director | SELL | 14.0K | $18.50 | $259K |